Concepedia

Publication | Open Access

Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes

DOIFull Paper Access

32

Citations

26

References

2016

Year

Aarti Ramanathan, Viktoria Gusarova, Neil Stahl, Anne Gurnett-Bander, Christos A. Kyratsous
PLoS ONE

Abstract

These results suggest that inhibition of PCSK9 with alirocumab has no effect on CD81 and does not result in increased susceptibility to HCV entry.

References

YearCitations

Page 1